Capmatinib
- Generic Name
- Capmatinib
- Brand Names
- Tabrecta
- Drug Type
- Small Molecule
- Chemical Formula
- C23H17FN6O
- CAS Number
- 1029712-80-8
- Unique Ingredient Identifier
- TY34L4F9OZ
- Background
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many...
- Indication
用于治疗局部晚期或转移性MET外显子14跳跃（METEX 14）突变的非小细胞肺癌（NSCLC）患者。
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable, locally advanced Non-Small Cell Lung Carcinoma (NSCLC)
- Associated Therapies
- -
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 40
- Registration Number
- NCT06054191
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University, Guangzhou, Guangdong, China
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 68
- Registration Number
- NCT05675683
- Locations
- 🇺🇸
18 Novartis Investigative Sites in the US, East Hanover, New Jersey, United States
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 66
- Registration Number
- NCT05642572
- Locations
- 🇺🇸
Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, United States
🇺🇸Saint Francis Cancer Center, Colorado Springs, Colorado, United States
🇺🇸Illinois CancerCare-Eureka, Eureka, Illinois, United States
Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Timothy Burns, MD, PHD
- Registration Number
- NCT05567055
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT05488314
- Locations
- 🇰🇷
Gachon University Gil Hospital, Incheon, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Collin Blakely
- Target Recruit Count
- 3
- Registration Number
- NCT05435846
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05243641
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)
- Conditions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2023-01-06
- Target Recruit Count
- 182
- Registration Number
- NCT05154344
- Locations
- 🇫🇷
CHU, Tours, France
Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
- Conditions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 90
- Registration Number
- NCT05135845
- Locations
- 🇫🇷
Centre François Leclerc, Dijon, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Universitaire du Cancer, Toulouse, France
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT04926831
- Locations
- 🇺🇸
UCLA Oncology Hematology, La Jolla, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸Fairfax Northern Virginia Hem Onc, Fairfax, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.